| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/15/2022 | 228.95% | Canaccord Genuity | → $20 | Initiates Coverage On | → Buy |
| 08/17/2022 | 64.47% | HC Wainwright & Co. | $11 → $10 | Maintains | Buy |
| 01/31/2022 | 80.92% | HC Wainwright & Co. | $10 → $11 | Upgrades | Neutral → Buy |
| 04/09/2021 | 64.47% | HC Wainwright & Co. | $12 → $10 | Maintains | Neutral |
| 03/04/2021 | 97.37% | HC Wainwright & Co. | $24 → $12 | Downgrades | Buy → Neutral |
| 01/25/2021 | 360.53% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 05/20/2020 | -75.33% | HC Wainwright & Co. | $2.5 → $1.5 | Reiterates | → Buy |
| 11/20/2019 | -58.88% | HC Wainwright & Co. | $3 → $2.5 | Reiterates | → Buy |
| 09/05/2019 | -82.73% | Roth Capital | $4.25 → $1.05 | Downgrades | Buy → Neutral |
| 06/19/2019 | -50.66% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 05/23/2018 | 179.61% | Janney Montgomery Scott | → $17 | Initiates Coverage On | → Buy |
| 02/26/2018 | 80.92% | Canaccord Genuity | $7 → $11 | Maintains | Buy |
KemPharm Questions & Answers
The latest price target for KemPharm (NASDAQ: KMPH) was reported by Canaccord Genuity on September 15, 2022. The analyst firm set a price target for $20.00 expecting KMPH to rise to within 12 months (a possible 228.95% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for KemPharm (NASDAQ: KMPH) was provided by Canaccord Genuity, and KemPharm initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KemPharm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KemPharm was filed on September 15, 2022 so you should expect the next rating to be made available sometime around September 15, 2023.
While ratings are subjective and will change, the latest KemPharm (KMPH) rating was a initiated with a price target of $0.00 to $20.00. The current price KemPharm (KMPH) is trading at is $6.08, which is within the analyst's predicted range.